Full Breakdown
Trump Administration’s “Most-Favoured-Nation” Drug Pricing Push and Its Potential Ripple to Canada
By Drooid · · How we work
Trump Administration’s MFN Drug Pricing Initiative
The U.S. government announced a policy that obliges drug manufacturers to sell medicines in the United States at prices no higher than those paid in a set of 19 reference nations—including Canada, Europe, Australia, Japan and South Korea. The approach, known as “most-favoured-nation” (MFN) pricing, is being applied to brand-name drugs through agreements with 26 large pharmaceutical companies. In parallel, President Donald Trump sent letters to 17 major American drug makers demanding that they align U.S. prices with those offered to similarly sized, wealthy countries.
How the Policy Works and Intended Scope
Under the executive order signed in May, manufacturers that receive U.S. Medicaid rebates must match the lowest net price observed in any of the reference countries. The administration argues the move will lower Medicare spending, which the Lancet-published modelling by Dr. Thomas Hwang and colleagues suggests could be significant. However, the agreements contain redacted sections, and the exact financial terms remain undisclosed, making independent assessment difficult.
Official Statements & Responses
The pharmaceutical trade group Innovative Medicines Canada warned that MFN pricing could disrupt the Canadian market, potentially delaying the launch of new therapies and undermining confidence in price stability. Public Citizen, a U.S. consumer-advocacy organization, released copies of the redacted contracts, noting clauses that could enable companies to raise prices abroad or limit supply to preserve higher U.S. prices.
Concerns from Canadian Stakeholders
Canadian experts caution that manufacturers may respond to lost U.S. revenue by increasing Canadian prices, reducing discounts, or postponing product introductions. Associate professor Mina Tadrous (University of Toronto) explained that while MFN pricing does not automatically raise Canadian prices, it creates incentives for such adjustments. Innovative Medicines Canada emphasized the real-world impact on patients awaiting cancer, rare-disease, or first-in-class treatments. Family physician Nav Persaud observed that many Canadians already sacrifice medicines due to cost pressures, a situation that could worsen if drug prices rise.
Verbatim Quotes
- “We went from paying the highest drug prices in the world to paying the lowest drug prices in the world,” — Donald Trump, president
- “It basically says that the United States wishes to get the price that's being offered to similarly sized countries and similarly wealthy countries,” — Dr. Thomas Hwang, an assistant professor at Brigham and Women's Hospital in Boston
- “For Canadians waiting for a new cancer therapy, a rare disease treatment, or first-in-class medicine, these aren’t abstract policy debates. The changes could have serious consequences for them and their families,” — Innovative Medicines Canada, warn experts
- “People are paying a lot for food and for rent, and they don't have money left over at the end of the month to pay for medicines and medicines end up getting sacrificed,” — Nav Persaud, a family physician with St
- “That carveout is new from what the administration has told us in the months leading up to this as well what even the companies have disclosed,” — Dr. Thomas Hwang, an assistant professor at Brigham and Women's Hospital in Boston